Effects of InFat™ Product on Stool Biochemistry and Stool Characteristics in Formula-fed Term Chinese Infants

This study has been terminated.
(Study design changes were needed due to change of protocol to a multisite trial and updated set up)
Sponsor:
Information provided by:
Enzymotec
ClinicalTrials.gov Identifier:
NCT00480948
First received: May 30, 2007
Last updated: June 6, 2011
Last verified: August 2008

May 30, 2007
June 6, 2011
September 2008
April 2009   (final data collection date for primary outcome measure)
Stool biochemistry - soaped fatty acids [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
Stool biochemistry – soaped fatty acids
Complete list of historical versions of study NCT00480948 on ClinicalTrials.gov Archive Site
  • Stool biochemistry - total fatty acids and calcium content [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • Stool characteristics - 7days diaries [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • General health [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Anthropometric parameters [ Time Frame: 3-6 months ] [ Designated as safety issue: No ]
  • Stool biochemistry – total fatty acids and calcium content
  • Stool characteristics – 7days diaries
  • General health
  • Anthropometric parameters
  • Bone characteristics
  • Calcium content in stool
Not Provided
Not Provided
 
Effects of InFat™ Product on Stool Biochemistry and Stool Characteristics in Formula-fed Term Chinese Infants
Effects of InFat™ Product (High Sn-2 Palmitic Acid) on Stool Biochemistry and Stool Characteristics in Formula-fed Term Chinese Infants: a Triple-blind, Randomized, Placebo-controlled Trial

The purpose of this study is to demonstrate the efficacy of infant formula having proportion of palmitate in the sn-2 position comparable to human milk in Chinese term infants.

In human breast milk, and in most infant formulas more than 98% of this milk fat is in the form of triglycerides, which contain saturated and unsaturated fatty acids esterified to glycerol. Fatty acids in human milk-fat have a highly specific positional distribution on the glycerol backbone and this specific configuration is known to have a major contribution to the efficacy of this nutrient absorption.

Palmitic acid (C16:0), the major saturated fatty acid, is predominantly esterified to the sn-2 (β) position of the triglyceride in human milk. In contrast, palmitic acid in standard infant formulas is esterified to the sn-1 and sn-3 positions.

Infants fed with high sn-2 palmitic acid formula had softer stools, less constipation and better calcium absorption as compared to standard infant formula.

InFat™ is structured triglyceride fat ingredient with high levels of palmitic acid at sn-2 position.

The primary objective of this trial is to demonstrate that feeding Chinese term infants, with formula having proportion of palmitate in the sn-2 position comparable to human milk, reduces calcium-soaps formation.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Healthy
  • Behavioral: Infant formula feeding (InFat™)
    Infant formula with InFat™ oil (containing ~49% of C16:0 at sn-2 position), 24 wk
  • Dietary Supplement: Control
    Standard vegetable oil based infant formula
  • Active Comparator: 1
    Infant formula with InFat™ oil(containing ~49% of C16:0 at sn-2 position).
    Intervention: Behavioral: Infant formula feeding (InFat™)
  • Placebo Comparator: 2
    Standard vegetable oil based infant formula
    Intervention: Dietary Supplement: Control
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
80
August 2009
April 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Term infants: gestation 37-40 weeks
  • Birth weight 2500-4000 g
  • Apparent good health
  • The infant is a product of normal pregnancy and delivery.

Exclusion Criteria:

  • Any maternal disease (psychological or disabled) or socioeconomic problems that may interfere with the mother's ability to take care of her infant
  • Major congenital abnormality or chromosomal disorder with a clinical significance that can be detected at birth, clinically significant
  • Disease requiring mechanical ventilation or medication treatment at the first week (not including photo treatment for infantile hepatitis)
  • Born with a 5- or 10-minute Apgar score <7
  • Any suspected or known metabolic or physical limitations interfering with feeding or normal metabolism (require a special formula)
  • Breast-feeding for a week or over.
  • Any other reason that, in the opinion of the investigator, prevents the subject from participating in the study.
Both
up to 8 Days
Yes
Contact information is only displayed when the study is recruiting subjects
China
 
NCT00480948
InFat™001
Not Provided
Yael Lifshitz PhD, Enzymotec
Enzymotec
Not Provided
Principal Investigator: Yi Xiang Su, MD Professor Sun Yat-sen University
Principal Investigator: Yuming Chen, PhD Sun Yat-sen University
Enzymotec
August 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP